Cancer Archives

News and Trends 12 Sep 2022

Enterome presents more data on therapeutic cancer treatment

Clinical stage biopharma company Enterome has presented new data from its two phase 1/2 clinical trials of its OncoMimics cancer immunotherapy EO2401. The trails are in combination with nivolumab (Opdivo) +/- bevacizumab (Avastin), in patients with first progression/recurrence of glioblastoma (ROSALIE trial), and in combination with nivolumab in patients with non-resectable adrenocortical carcinomas (ACC) and […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Astellas, Seagen and Merck give details on urothelial cancer treatment

Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […]

September 12, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

Clinical oncology company Ayala Pharmaceuticals, Inc. has announced updated, positive interim results from part A of its ongoing RINGSIDE pivotal phase 2/3 clinical trial evaluating investigational new drug AL102 in desmoid tumors. Ayala Pharmaceutical’s AL102 is a selective, oral gamma-secretase inhibitor. The data are being featured in an oral presentation at the European Society for […]

September 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Reveal Genomics reveals more HER2DX breast cancer validation data

Reveal Genomics, S.L. says it has received more validation of HER2DX, the world’s first specialized genomic test for HER2+ breast cancer. Valentina Guarneri from the University of Padova presented the data at the European Society of Medical Oncology Congress 2022 in Paris, France. The data obtained from the analysis of tumor samples from the PerELISA […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Shasqi moves to phase 2 solid tumor study

Shasqi, a clinical-stage biotechnology company developing oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform says it has opened the phase 2 part of its phase 1/2a clinical study to further assess SQ3370 in anthracycline-naïve patients. The phase 2 study follows the company’s presentation at the European Society for Medical Oncology (ESMO) […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Sep 2022

First patient dosed in China trial with drug to treat non-Hodgkin lymphoma

The dosing of the first patient at a clinical trial in China for patients with relapsed/refractory non-Hodgkin lymphoma (NHL) was announced yesterday (September 7). CASI Pharmaceuticals and BioInvent International AB are running the phase 1, dose-escalation and expansion study of BI-1206. The treatment is a fully human monoclonal antibody (mAb) that targets FcyRIIB, in combination […]

September 8, 2022 - 2 minutesmins - By Liza Laws

Startup Scout 8 Sep 2022

Stratosvir is overcoming the viral immunotherapy delivery bottleneck

The U.K. startup Stratosvir is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. Cancer immunotherapies have made great strides in the last decade, with some of the most important advances including CAR-T cell therapy and checkpoint inhibitors. One oncology field […]

September 8, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 8 Sep 2022

Lutris Pharma radiation trial brings positive results for breast cancer patients

Top line results from a clinical trial treating breast cancer patients with radiation dermatitis (RD) have been positive. Lutris Pharma, based in Israel, is a biopharma company focused on improving cancer therapies. It announced its results from the open label part 1 and double blinded part 2 of it phase 1/2 trial yesterday (September 7). […]

September 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

OncoBone signs deals with three partners to work on bone metastases

OncoBone Ventures has signed cooperation framework agreements with three partners. The company is a U.K. start up biotech looking to develop novel therapies for cancer patients with currently incurable bone metastases. The partners are: Okayama University in Japan, the University of Bradford in the U.K., and The Development Center for Biotechnology in Taiwan. The agreements […]

September 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Oncopeptides receives grant for NK-cell engager project in multiple myeloma

Oncopeptides AB has received a SEK 5 million ($465,000) research grant from Sweden’s Innovation Agency. The Swedish biotech company, which focuses on R&D of therapies for difficult-to-treat hematological diseases, will use the funds to develop a preclinical proof of concept (PoC) for a novel synthetic small polypeptide for the treatment of multiple myeloma. The compound […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, has announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo (cemiplimab). The supply agreement with Regeneron will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Lytix Biopharma expanding advanced melanoma study to Europe

Lytix Biopharma, a Norwegian immuno-oncology company, has received regulatory approval from European authorities to start its ATLAS-IT-05 study in three European countries. ATLAS-IT-05 is a phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Enterome presents more data on therapeutic cancer treatment

Astellas, Seagen and Merck give details on urothelial cancer treatment

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

Reveal Genomics reveals more HER2DX breast cancer validation data

Shasqi moves to phase 2 solid tumor study

First patient dosed in China trial with drug to treat non-Hodgkin lymphoma

Stratosvir is overcoming the viral immunotherapy delivery bottleneck

Lutris Pharma radiation trial brings positive results for breast cancer patients

OncoBone signs deals with three partners to work on bone metastases

Oncopeptides receives grant for NK-cell engager project in multiple myeloma

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

Lytix Biopharma expanding advanced melanoma study to Europe

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!